Lv4
490 积分 2026-07-21 加入
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
5小时前
已完结
International Endocervical Adenocarcinoma Criteria and Classification (IECC): An Independent Cohort With Clinical and Molecular Findings
5小时前
已完结
Molecular and microenvironmental landscapes of human papillomavirus-independent invasive squamous cell carcinoma of the vulva
7小时前
已完结
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
7小时前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
7小时前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
7小时前
已完结
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
7小时前
已完结
The evidence framework for precision cancer medicine
8小时前
已完结
皖公网安备34019202002308
